GlassScriptPhysician profile
Mackensley Gray
NPI 1104668797
$4,231.34
in general payments reported to CMS, 2019-2025
21 companies · $2,205 in 2025
The $2,205 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $2,027 · 2025: $2,205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,127 · Travel and Lodging: $1,104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,127.18 |
| Travel and Lodging | $1,104.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,989.50 | 2024-2025 | Minimed 780g |
| Novo Nordisk INC | $461.59 | 2024-2025 | Ozempic, Rybelsus |
| Tandem Diabetes Care, INC. | $264.63 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Sequel Med Tech, LLC | $230.17 | 2024-2025 | Twiist |
| Corcept Therapeutics | $224.16 | 2024-2025 | Korlym |
| Lilly USA, LLC | $219.45 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $199.52 | 2024-2025 | |
| Amgen INC. | $128.21 | 2024-2025 | Evenity, Tepezza, Repatha |
| Xeris Pharmaceuticals, INC. | $109.50 | 2024-2025 | Recorlev, Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $63.20 | 2024-2025 | |
| Esperion Therapeutics, INC. | $61.73 | 2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.91 | 2024-2025 | Jardiance, Synjardy |
| Ibsa Pharma INC. | $59.08 | 2024-2025 | Tirosint, Licart, Flector |
| Glaxosmithkline, LLC. | $35.78 | 2025 | Shingrix, Arexvy |
| Beta Bionics, INC. | $21.96 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $20.86 | 2025 | Omnipod |
| Ascendis Pharma Endocrinology INC | $18.07 | 2025 | Yorvipath |
| Phathom Pharmaceuticals, INC. | $17.81 | 2025 | Voquezna |
| Abbott Laboratories | $15.55 | 2025 | Freestyle Libre 3 |
| Tolmar, INC. | $14.87 | 2024 | |
| Recordati_rare_diseases_inc. | $14.79 | 2024 | Signifor Lar, Isturisa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mackensley Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.